Axonics Inc.

AI Score

XX

Unlock

70.98
null (null%)
At close: Nov 14, 2024, 9:00 PM

Company Description

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems.

The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention.

Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction.

The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.

It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally.

The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021.

Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Axonics Inc.
Axonics Inc. logo
Country United States
IPO Date Oct 31, 2018
Industry Medical - Devices
Sector Healthcare
Employees 797
CEO Raymond W. Cohen

Contact Details

Address:
26 Technology Drive
Irvine, California
United States
Website https://www.axonics.com

Stock Details

Ticker Symbol AXNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001603756
CUSIP Number 05465P101
ISIN Number US05465P1012
Employer ID 45-4744083
SIC Code 3841

Key Executives

Name Position
Raymond W. Cohen Chief Executive Officer & Director
Guangqiang Jiang Ph.D. Chief Technology Officer
Kari Keese Chief Financial Officer
Rinda K. Sama Chief Operating Officer
Aaron Pettit General Counsel & Chief Compliance Officer
Alfred J. Ford Jr. Chief Commercial Officer
Dr. John Woock Ph.D. Executive Vice President, Chief Marketing & Strategy Officer
Dr. Karen L. Noblett M.A.S., M.D. Chief Medical Officer
Michael V. Williamson Esq., J.D. Senior Vice President, General & IP Counsel
Neil Bhalodkar Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Nov 25, 2024 15-12G Filing
Nov 15, 2024 25-NSE Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing